All News
Filter News
Found 808,679 articles
-
Dewpoint Therapeutics Appoints Lori Escobedo as Chief People Officer
9/28/2021
Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Lori Escobedo as Chief People Officer.
-
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
9/28/2021
Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA") has affirmed the resubmission of its New Drug Application ("NDA") for TLANDO®, its oral testosterone product, will be a Class 1 resubmission.
-
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine
9/28/2021
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that Trudhesa™ nasal spray is now available for prescription.
-
Arrowhead Earns $10 Million Phase 1 Milestone Payment
9/28/2021
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc.
-
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
9/28/2021
Dicerna Pharmaceuticals, Inc today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).
-
Portal Instruments Clinical Study Demonstrating Patient Preference for Needle-Free Injections Published in Drug Delivery
9/28/2021
Portal Instruments, developer of the Prime needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for Prime needle-free injections was published this month in the journal Drug Delivery.
-
Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing
9/28/2021
Hamilton Company and Rhinostics, an early-stage Harvard University spin-out company, are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows from collection to processing while also reducing the need for active labor involvement.
-
Foldax Completes Enrollment in Early Feasibility Study for TRIA Biopolymer Surgical Aortic Heart Valve
9/28/2021
Foldax®, Inc. today announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve.
-
POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor
9/28/2021
POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today released additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program called PNT2004.
-
CB Scientific, Inc. (CBSC) Announces the Launch of Direct-to-Consumer Heart Wellness Check-Up Program in Bangkok, Thailand
9/28/2021
CB Scientific. Inc. today announces the official launch of the "Heart Wellness Check-Up" program in Bangkok, Thailand through their authorized distributor Mango Wellness and My Cardia Thailand.
-
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
9/28/2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $30 million private placement to ten accredited investors.
-
BioSymetrics Expands Leadership Team to Support Rapid Growth
9/28/2021
BioSymetrics, an AI-powered drug discovery company, today announced the appointments of Stacie Calad-Thomson as Chief Strategy Officer and Head of Drug Discovery, Matt Fusco as Chief Operating Officer, and Amanda Guisbond as Vice President of Marketing and Communications.
-
Thermo Fisher Scientific Launches SpeciMAX Stabilized Saliva Collection Kit
9/28/2021
As global SARS-CoV-2 research efforts continue, labs are increasingly conducting scientific studies using banked saliva samples, taking advantage of a sample type which is easy to access and non-invasive.
-
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
9/28/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
-
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
9/28/2021
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced new 12-month safety data from the pivotal Phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for treatment of neovascular age-related macular degeneration (wet AMD).
-
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
9/28/2021
Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a $2.97 million Phase 2 STTR Study Grant.
-
20/20 GeneSystems Launches First Accelerator Facility for Innovative Clinical Lab Tests
9/28/2021
20/20 GeneSystems, Inc., (“20/20”), announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S.
-
ONPATTRO (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR)
9/28/2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is pleased to announce that ONPATTRO® (patisiran) is now reimbursed almost everywhere in Canada for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy.
-
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
9/28/2021
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo ®
-
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
9/28/2021
I-Mab (the "Company") (Nasdaq: IMAB),today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted the Company's IND application to initiate a phase 2 trial for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda®) in patients with selected solid tumors in China.